FDA Lymerix Study To Test Potential Genetic Marker For Adverse Events
Executive Summary
GlaxoSmithKline's Lymerix will be the subject of an FDA case-control study investigating a potential genetic marker for adverse reactions to the Lyme disease vaccine.